Skip to main content
Clinical Trials/NL-OMON31625
NL-OMON31625
Completed
Not Applicable

A Prospective, Multi-centre Study to Evaluate the Clinical Performance of the GYNECARE PROLIFT +M* Pelvic Floor Repair System as a Device for Pelvic Organ Prolapse - The GYNECARE PROLIFT

Ethicon_Johnson & Johnson Medical Ltd0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prolapse
Sponsor
Ethicon_Johnson & Johnson Medical Ltd
Enrollment
20
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Ethicon_Johnson & Johnson Medical Ltd

Eligibility Criteria

Inclusion Criteria

  • 1\. Candidates with symptomatic pelvic organ prolapse of ICS POP\-Q Stage III or IV, suitable for surgical repair. Perineal repair, vaginal hysterectomy and/or mid urethral sling procedures for incontinence may be performed concurrently.
  • 2\. Age \>\<\= 18 years.
  • 3\. Agrees to participate in the study, including completion of all study\-related procedures, evaluations and questionnaires, and documents this agreement by signing the Ethics Committee / IRB approved informed consent.

Exclusion Criteria

  • 1\. Additional surgical intervention for POP repair concurrent to the Gynecare Prolift \+M procedure (e.g. paravaginal repair, sacrocolpopexy, colporrophy in a non\-Gynecare Prolift\+M treated compartment).
  • 2\. Previous repair of pelvic organ prolapse involving insertion of mesh.
  • 3\. Previous hysterectomy within 6 months of scheduled surgery.
  • 4\. Experimental drug or experimental medical device within 3 months prior to the planned procedure.
  • 5\. Active genital, urinary or systemic infection at the time of the surgical procedure. Surgery may be delayed in such subjects until the infection is cleared.
  • 6\. Coagulation disorder or on therapeutic anticoagulant therapy at the time of surgery.
  • 7\. History of chemotherapy or pelvic radiation therapy.
  • 8\. Systemic disease known to affect bladder or bowel function (e.g. Parkinson\*s disease, multiple sclerosis, spina bifida, spinal cord injury or trauma).
  • 9\. Current evaluation or treatment for chronic pelvic pain (e.g. interstitial cystitis, endometriosis, coccydynia, vulvadynia).
  • 10\. Nursing or pregnant or intends future pregnancy.

Outcomes

Primary Outcomes

Not specified

Similar Trials